Biohaven (BHVN) Expected to Announce Quarterly Earnings on Thursday

Biohaven (NYSE:BHVN - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Biohaven to post earnings of ($1.64) per share and revenue of $1.25 million for the quarter.

Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, analysts expect Biohaven to post $-9 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Biohaven Trading Down 16.0 %

Shares of NYSE:BHVN traded down $3.62 on Tuesday, reaching $19.00. 3,301,795 shares of the company's stock were exchanged, compared to its average volume of 1,168,446. Biohaven has a twelve month low of $15.79 and a twelve month high of $55.70. The company has a fifty day moving average of $24.26 and a 200-day moving average of $36.04. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -2.03 and a beta of 1.18.

Insiders Place Their Bets

In other Biohaven news, Director John W. Childs purchased 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of $30.47 per share, with a total value of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 16.00% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on BHVN shares. HC Wainwright restated a "buy" rating and set a $54.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Robert W. Baird decreased their target price on shares of Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a report on Monday, April 28th. JPMorgan Chase & Co. cut their price target on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Finally, William Blair raised shares of Biohaven to a "strong-buy" rating in a research note on Thursday, April 24th. Fourteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Biohaven has an average rating of "Buy" and a consensus price target of $62.54.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.